(urokinase for injection)
Kinlytic™ (urokinase for injection) is a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture. The principal active ingredient of Kinlytic™ is the low molecular weight form of urokinase, and consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons.
Kinlytic™ is indicated in adults:
- For the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments.
- For the lysis of pulmonary emboli accompanied by unstable hemodynamics, i.e., failure to maintain blood pressure without supportive measures.
The diagnosis should be confirmed by objective means, such as pulmonary angiography or non-invasive procedures such as lung scanning.
Media Articles Related to Kinlytic (Urokinase)
Pulmonary Embolism (Blood Clot in the Lung)
Source: MedicineNet enoxaparin Specialty [2015.11.20]
Title: Pulmonary Embolism (Blood Clot in the Lung)
Category: Diseases and Conditions
Created: 3/20/2008 12:00:00 AM
Last Editorial Review: 11/20/2015 12:00:00 AM
Published Studies Related to Kinlytic (Urokinase)
Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. [2011.01]
The aim of our study was to investigate the pharmacokinetics and safety of human tissue urokinase type plasminogen activator (HTUPA) in healthy Chinese subjects after intravenous administration. Thirty-two subjects were given intravenous injection doses of 5-35 mg of HTUPA for safety evaluation... No serious adverse events were reported by the subjects or revealed by clinical or laboratory examinations, suggesting the given doses were safe and well tolerated.
Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial. [2009.12.29]
BACKGROUNDS: Urokinase (UK) 2 200 U/kg.h for 12 hours infusion(UK-12 h)is an ACCP recommended regimen in treating acute pulmonary embolism (PE). It is unclear whether this dose and time can be reduced further. We compared the efficacy and safety of 20, 000 U/kg for 2 hours (UK-2 h) with the UK-12 h regime in selected PE patients... CONCLUSIONS: The UK-2 h regimen exhibits similar efficacy and safety as the UK-12 h regimen for acute PE.
[Thrombolysis of rabbit's pulmonary embolism with thrombus-targeted urokinase immune liposome] [2009.11]
OBJECTIVE: To develop thrombus-targeted urokinase immune liposome through incorporating D-dimer monoclonal antibody (DDmAb) to liposome and observe the thrombolytic efficiency in a rabbit pulmonary thromboembolism (PE) model... CONCLUSION: Acute PE could be successfully treated by the thrombus-targeted urokinase immune liposome with D-dimer monoclonal antibody.
Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial. [2009.07]
The purpose of this study was to assess whether regular instillation of urokinase during abscess drainage leads to an improved outcome compared to saline irrigation alone. One hundred patients referred for image-guided abdominal abscess drainage were randomized between thrice daily urokinase instillation or saline irrigation alone...
Use of urokinase in percutaneous drainage of large breast abscesses. [2009.04]
OBJECTIVE: The purpose of this study was to evaluate intracavitary urokinase therapy versus irrigation with a saline solution in percutaneous drainage of large breast abscesses... CONCLUSIONS: Percutaneous drainage of large breast abscesses in nonlactating women with intracavitary urokinase irrigation is a simple and safe procedure. It reduces the treatment time and improves the clinical course of patients more than conventional drainage with saline irrigation.
Clinical Trials Related to Kinlytic (Urokinase)
Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia [Terminated]
In this randomized clinical trial (RCT) the investigators are trying to find out whether a
low-dose therapy with daily short infusions of urokinase using 10 to 21 doses over a maximum
of 30 days is capable of prolonging the survival time without major amputation.
Dornase Alfa and Urokinase for Kids With Pleural Empyema [Recruiting]
The purpose of this study is to determine whether intrapleural treatment with Dornase alfa
plus Urokinase improves clinical outcome compared to Urokinase alone in children with
complicated parapneumonic effusions
Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood [Completed]
A great controversy exists about which is the best method to perform the evacuation of the
collection. The purpose of this study is to evaluate which is the best initial treatment to
drain complicated parapneumonic empyema (stages II and III) in children: the present study
raises a hypothesis of equivalence between both arms of treatment (chest drainage plus
intrapleural urokinase or videothoracoscopic debridement).
Intrapleural Urokinase for Retained Hemothorax [Active, not recruiting]
Intrapleural thrombolytic treatment with urokinase for retained hemothorax is effective and
safe. However, previous study was limited in prospective observation study without control
Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema [Completed]
- Main objective: To evaluate the efficacy and safety of intrapleural alteplase vs
urokinase in patients with complex complicated parapneumonic pleural effusion and
- To evaluate the pleural and plasmatic levels of the fibrinolytic system markers
after the treatment with alteplase vs urokinase
- To evaluate the safety of alteplase in the treatment of complex complicated
parapneumonic pleural effusion and empyema
2. Design: Multicentric, randomized, parallel, controlled and double blind
3. Main variable: Percentage of curation
4. Study population and number of patients: 204 patients with complex complicated
parapneumonic pleural effusions and empyema
5. Duration of the treatment: Three days (main variable), and optional three days